BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 36825002)

  • 1. Treatment of extranodal NK/T-cell lymphoma: From past to future.
    Yan Z; Yao S; Wang Z; Zhou W; Yao Z; Liu Y
    Front Immunol; 2023; 14():1088685. PubMed ID: 36825002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The landscape of new drugs in extranodal NK/T-cell lymphoma.
    Wang L; Li LR; Zhang L; Wang JW
    Cancer Treat Rev; 2020 Sep; 89():102065. PubMed ID: 32653806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK/T-cell lymphoma.
    Qi F; Xie Y; Wang D; Chai Y; Chen B; Sun Y; Liu W; Qi S; Wei Y; Fang H; Zhao D; Gui L; Yang Y; Feng X; Ding N; Mi L; Shu S; Li Y; Song Y; Dong M; Zhu J
    Ann Hematol; 2022 Sep; 101(9):2021-2034. PubMed ID: 35798977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage.
    Zeng L; Huang W; Cao Z; Zheng B; Liu X; Guo L; Feng X
    Ann Hematol; 2019 Jun; 98(6):1467-1476. PubMed ID: 30895352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell lymphoma.
    Wang L; Yang J; Wang HN; Fu RY; Liu XD; Piao YS; Wei LQ; Wang JW; Zhang L
    Theranostics; 2021; 11(2):925-940. PubMed ID: 33391513
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study.
    Zheng X; He X; Yang Y; Liu X; Zhang LL; Qu BL; Zhong QZ; Qian LT; Hou XR; Qiao XY; Wang H; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Zhang HL; Su H; Song YQ; Zhu J; Zhang YJ; Huang HQ; Wang Y; Chen F; Yin L; Qi SN; Li YX
    ESMO Open; 2021 Aug; 6(4):100206. PubMed ID: 34242966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose extended-field radiotherapy plus chemotherapy improved survival in extranodal NK/T-cell lymphoma in a real-life setting: results from the multicenter T-Cell Brazil Project.
    de Pádua Covas Lage LA; Machado PPF; Reichert CO; Miranda E; Culler HF; da Siqueira SAC; de Oliveira Costa R; Miyashiro DR; Sanches JA; Rocha V; Chiattone CS; Pereira J
    Sci Rep; 2022 Nov; 12(1):20557. PubMed ID: 36446856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma.
    Niu SQ; Yang Y; Li YY; Wen G; Wang L; Li ZM; Wang HY; Zhang LL; Xia YF; Zhang YJ
    Chin J Cancer; 2016 Apr; 35():34. PubMed ID: 27044275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of pSTAT3 and PD-L1 in extranodal NK/T cell lymphoma and its clinical significance].
    Zhang F; Luo DL; Chen Y; Yan JH; Luo LQ; Liu J; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2020 Oct; 49(10):999-1002. PubMed ID: 32992412
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study.
    Li JW; Li YJ; Zhong MZ; Liu XL; Li J; Li KL; Liu XY; Zhou F; OuYang Z; Sun ZY; Huang LJ; He JQ; Zhou H; Yi PY
    Eur J Haematol; 2018 Mar; 100(3):247-256. PubMed ID: 29194798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression.
    Cho J; Kim SJ; Park WY; Kim J; Woo J; Kim G; Yoon SE; Ko YH; Kim WS
    Mod Pathol; 2020 Apr; 33(4):603-615. PubMed ID: 31653980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
    Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
    Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
    Lim SH; Hong JY; Lim ST; Hong H; Arnoud J; Zhao W; Yoon DH; Tang T; Cho J; Park S; Ko YH; Kim SJ; Suh C; Lin T; Kim WS
    Ann Oncol; 2017 Sep; 28(9):2199-2205. PubMed ID: 28911074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).
    Kim M; Kim TM; Kim KH; Keam B; Lee SH; Kim DW; Lee JS; Jeon YK; Kim CW; Heo DS
    Ann Hematol; 2015 Mar; 94(3):437-44. PubMed ID: 25300500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.
    Haverkos BM; Pan Z; Gru AA; Freud AG; Rabinovitch R; Xu-Welliver M; Otto B; Barrionuevo C; Baiocchi RA; Rochford R; Porcu P
    Curr Hematol Malig Rep; 2016 Dec; 11(6):514-527. PubMed ID: 27778143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel prognostic model based on ferritin and nomogram-revised risk index could better stratify patients with extranodal natural killer/T-cell lymphoma.
    Liu X; Liang Y; Shen Z; Wei L; Yang J; Piao Y; Sang W; Li P; Wang L
    Cancer Med; 2023 May; 12(9):10660-10671. PubMed ID: 36924334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Incidence and treatment of extranodal natural killer/T-cell lymphoma nasal type. Hungarian experiences].
    Bakos A; Szomor Á; Schneider T; Miltényi Z; Marton I; Borbényi Z; Pammer J; Krenács L; Bagdi E; Piukovics K
    Orv Hetil; 2017 Oct; 158(41):1635-1641. PubMed ID: 29025287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De Novo Testicular Extranodal NK/T-Cell Lymphoma: A Clinicopathologic Study of 21 Cases With Review of Additional 18 Cases in the Literature.
    Huang Y; Shi X; Zhong P; Wang Y; Xiao H; Zhou X; Yun J
    Am J Surg Pathol; 2019 Apr; 43(4):549-558. PubMed ID: 30589649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis.
    Pokrovsky VS; Vinnikov D
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):759-768. PubMed ID: 28621166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in immunotherapy of extranodal NK/T cell lymphoma].
    Hao DQ; Li LQ; Li MC; Gong LL
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Dec; 54(12):949-953. PubMed ID: 31887826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.